AstraZeneca
$158.62Change from previous close: −1.77%Absolute change: −$2.85
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $246.19B
- Enterprise value
- $277.9B
- P/E (trailing 12 months)
- 23.6
- Forward P/E
- 13.7
- PEG
- 1.15
- Price/book
- 4.90
- Price/sales
- 4.01
- EV/EBITDA
- 14.0
- EV/revenue
- 4.53
Profitability and growth
- Gross margin
- 81.7%
- Operating margin
- 23.5%
- Net margin
- 17.0%
- ROE
- 22.0%
- ROA
- 8.0%
- Revenue growth (year over year)
- 6.4%
- Earnings growth (year over year)
- 2.5%
Financial health
- Total cash
- $4.97B
- Total debt
- $32.35B
- Debt/equity
- 0.64
- Current ratio
- 0.89
- Quick ratio
- 0.66
Dividends
- Annual dividend per share
- $3.20
- Dividend yield
- 2.0%
- Payout ratio
- 47.4%
- Ex-dividend date
- August 7, 2026
Analysts and estimates
- Average price target
- $212.17
- Median price target
- $215.00
- High price target
- $240.00
- Low price target
- $184.00
- Number of analysts
- 11
- Consensus
- Strong buy
- Forward EPS
- $11.58
- EPS estimate, current year
- $10.09
Shares and trading
- Beta
- 0.21
- Average volume
- 3.4M
- Shares outstanding
- 1.55B
- Float
- 1.54B
- Institutional ownership
- 65.0%
- Insider ownership
- 0.1%
- Short interest (% of float)
- 0.1%
- Short ratio (days)
- 0.65